Ethan M. Shevach

Ethan M. Shevach is an advisor at TeraImmune who has dedicated their career to developing Disease-targeting Foxp3+ T regulatory T cells for personalized Treg therapy. Ethan began their work in this area as a postdoctoral fellow at USUHS from January 2012 to June 2015. Ethan then became a research assistant professor at MED, USUHS, from July 2015 to March 2018. In April 2018, they took on the role of vice president of research at TeraImmune LLC, where they worked until August 2019. Ethan returned to their previous company, TeraImmune, in September 2019 to assume their current position.

Ethan M. Shevach received their Doctor of Philosophy (Ph.D.) in Biochemistry from Chungnam National University.